Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

NCT04669951 | Completed

• 1 other identifier: uPAR ECV
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.

Conditions

Esophagus Cancer, Adenocarcinoma

Keywords

urokinase plasminogen activator receptor; uPAR; Cardia; Adenocarcinoma; Immunohistochemistry

Outcome Measures

Primary Outcomes (2)

• uPAR microexpression

  Our primary objective is to investigate uPAR microexpression in gastroesophageal adenocarcinomas both qualitatively and semi-quantitatively. This will be done by a pathology analysis of gastroesophageal cancer resections.

  Up to 6 months

• Tumor-to-background ratio

  A pathology staining will determine the uPAR in the tumor compared with the healthy cells.

  Up to 6 months

Secondary Outcomes (1)

• uPAR in patient groups

  Up to 6 months

Study Arms (1)

uPAR expression

EXPERIMENTAL

Immunohistochemistry

Other: uPAR immunohistochemistry

Interventions

uPAR immunohistochemistry OTHER

Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression

uPAR expression

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years old.
• Patients who underwent curatively intended surgery for gastroesophageal cancer
• Patients who underwent surgery after 01-01-2016.

You may not qualify if:

• Patients who applied for an exception from medical research at the "National Registry of Tissue Use."
• Patients with other histological subtypes than adenocarcinoma.

Sponsors & Collaborators

• Michael Patrick Achiam: lead

Study Sites (1)

Rigshospitalet

Copenhagen, Capital Region, 2100, Denmark

Location

MeSH Terms

Conditions

Adenocarcinoma Of Esophagus; Adenocarcinoma

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Michael Achiam, MD., Ph.D

  Rigshospitalet, Department of Surgical Gastroenterology

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Consultant, MD, DMSci, Ph.D., FEBS-OG, Ass. Professor

Model Details: The patients will be drawn from the existing clinical biobank. The biobank is located at the department of pathology, Rigshospitalet. From this clinical biobank, a new temporary research biobank will be made. Supplementary sections from formalin-fixed paraffin embedded (FFPE) blocks containing tumor tissue will be cut and Haematoxylin and eosin (HE) and immunohistochemical (IHC) staining will be performed.

Study Record Dates

• First Submitted: December 2, 2020
• First Posted: December 17, 2020
• Study Start: November 18, 2019
• Primary Completion: November 30, 2020
• Study Completion: November 30, 2020
• Last Updated: June 3, 2021

Record last verified: 2021-06

Locations

DK (1)